Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan - An economic evaluation of acute treatment in moderate to severe migraineurs

Headache Quarterly

Volumn 8, Issue 3, 1997, Pages 237-246

  Larbig, Wolfgang ^a   Brüggenjürgen, Bernd ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Glaxo Wellcome GmbH and Co   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAFERGOT; DIHYDROERGOTAMINE MESILATE; ERGOTAMINE TARTRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; WIGRAINE;

ADULT; ANALGESIC ACTIVITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0030802823     PISSN: 10597565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baron JC, Bousser MG. Controlled therapeutic tests in migraine. Neurol Rev. 1982; 138:279-295.
2. Brüggenjürgen B. Lebensqualität und Volkswitrschaftliche Kosten der Migräne in Deutschland. Bonn: Asgard Verlag; 1994.
3. Bullinger M, Brüggenjürgen B, Larbig W, Laurich F. Efficacy and quality of life under customary treatment and after four months' treatment with sumatriptan. In: Rose FC (ed). New Advances in Headache Research 4. London: Smith-Gordon; 1994; 309. (Abstract)
4. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa: CCOHTA; 1994.
5. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ. 1992; 2:103-115.
6. Drummond M. Cost of illness: A major headache? Pharmacoeconomics. 1992; 2:1-4.
7. Ensink F-BM, Bautz M, Brüggenjürgen B, Hanekop G-G. Migräneprävalenz in Deutschland. Schmerz. 1994; 8:155-161.
8. Göbel H, Petersen-Braun M, Soyka D. Die Prävalenz von Kopfschmerzen in Deutschland. Schmerz. 1993; 7:287-297.
9. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8(suppl 7):1-96.
10. Jones A, Harrop C. Study of migraine and the treatment of acute attacks in industry. J int Med Res. 1980; 8:321-325.
11. Lipton RB, Stuart WF. The epidemiology of migraine. Eur Neurol. 1994; 34:6-11.
12. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the U. S. Pharmacoeconomics. 1992; 2:67-76.
13. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother. 1995; 5:295-309.
14. Pryse-Philips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiological and societal impact of migraine and tension-type headache. J Can Sci Neurol. 1992; 19:333-339.
15. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother. 1995; 5:319-328.
16. Statistisches Bundesamt. Wo bleibt die Ziet. In: Die Zeitverwendung der Bevölkerung in Deutschland. Wiesbaden: Bundesministerium für Familie und Senioren; 1994.
17. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FFH. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics. 1995; 7:170-179.